Table of Contents
HENDERSON, Nev. – Leading Edge Pharms, (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, Tuesday announced the opening of the LENCURA Labs Research and Innovation Center in Carlsbad, Calif. The investment includes advanced organic medical chemists, research instruments and equipment dedicated to accelerating Leading Edge Pharms’ technical expertise and new product development.
“We believe cannabinoids are the medical science market of the future,” said Dr. Daniel Holsworth, chief science officer of LEP. “By enhancing our platform with R&D capabilities and key partner alliances, LEP is now well-positioned to implement clinical studies to target specific medical conditions and demonstrate the efficacy of new cannabinoid therapies and delivery systems. Through research testing in animal models, cellular lines, and human trials, LENCURA Labs will directly add further value in support of our product innovations that have the potential to improve millions of lives and unlock applications for many poorly-treated maladies.”
LENCURA Labs will allow LEP to leverage a growing inventory of intellectual property in neuroscience and pain. LEP’s R&D activities will focus on the development of safe and effective topical cannabinoid formulations as a step-wise approach to pain management therapy.
David Chadwick, chief executive officer of LEP said, “Our goal is to advance the development of proprietary cannabinoid products. I am confident that the new lab will allow us to optimize our existing product offerings and take product development to new heights. We believe the clinical work that will drive innovation at LENCURA Labs may soon be used to help tackle some of the largest public health problems of our time, including the opioid drug epidemic.”
